Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Potent corticosteroid + antibacterial

Betamethasone with fusidic acid

Brand names: Fucibet

Used in: Acute Red Eye

A topical fixed-combination preparation of the potent corticosteroid betamethasone with the antibacterial fusidic acid, used for inflammatory skin conditions such as eczema where secondary staphylococcal infection is present.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Betamethasone dampens cutaneous inflammation and immune response, while fusidic acid inhibits bacterial protein synthesis, active chiefly against Staphylococcus aureus.

Prescribing in practice

  • Topical fusidic acid use should be short and targeted because widespread or repeated exposure drives Staphylococcus aureus resistance.
  • Avoid prolonged use of the potent steroid on the face and flexures and avoid occlusion, which raises absorption.
  • Reserve for clinically infected inflammatory dermatoses rather than routine eczema maintenance.

Monitoring

Reassess after a short defined course, stopping the antibacterial once infection is controlled and switching to a plain emollient or steroid for ongoing eczema.

Counselling the patient

  • Use only for the limited period advised and do not keep treating once the skin has settled.
  • Apply thinly to affected skin and avoid the eyes.

Evidence & guidelines

Antimicrobial stewardship guidance and the SPC support short, targeted courses of topical fusidic acid to limit resistance.

Reference: NICE NG198; BAD; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways